Macular Edema following Retinal Vein Occlusion Macular Edema following Retinal Vein Occlusion

Under-standing
MEfRVO

What is Macular Edema following Retinal Vein Occlusion (MEfRVO), and what can it do to your eyes?

WHAT IS RVO?

RVO is a serious eye condition that can quickly get worse or lead to a loss of vision. The good news is that treatment options are available, and you've taken steps to help manage your RVO.

RVO occurs when a blood vessel in the retina becomes blocked, often by a blood clot. When fluid leaks into the macula as a result of the blocked blood vessel, it is called Macular Edema following Retinal Vein Occlusion, or MEfRVO. There are two types of MEfRVO: Macular Edema following Central Retinal Vein Occlusion (MEfCRVO) and Macular Edema following Branch Retinal Vein Occlusion (MEfBRVO).

WHAT IS MACULAR EDEMA FOLLOWING CENTRAL RETINAL VEIN OCCLUSION (MEfCRVO)?

CRVO occurs when the central retinal vein becomes blocked. MEfCRVO occurs when fluid leaks into the macula as a result of the blocked central retinal vein. CRVO makes up 2 out of every 10 diagnosed cases of RVO.

WHAT IS MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (MEfBRVO)?

BRVO occurs when one or more veins branching out from the central retinal vein become blocked. Most cases of RVO are BRVO (8 out of 10). MEfBRVO occurs when fluid leaks into the macula as a result of the blocked retinal vein.

Picture of effects of MEfCRVO on the eye, showing leaking blood and fluid, macular edema, macula, blocked central retinal vein, retina, optic nerve, and central retinal vein. Picture of effects of MEfBRVO on the eye, showing leaking blood and fluid, macular edema, macula, blocked blood vessel, retina, optic nerve, and branch retinal veins.
MEfCRVO
MEfBRVO
Macular Edema following Retinal Vein Occlusion MEfRVO

WHAT CAN PUT YOU AT RISK FOR MEfRVO?

  • Being 50 years of age or older
  • Arteriosclerosis
  • Being overweight
  • Diabetes
  • Glaucoma
  • High blood pressure
  • Smoking
View study results for EYLEA, an anti-VEGF treatment for patients with MEfRVO.

See the Results of EYLEA

EYLEA has been studied in more than 3,000 people with certain diseases of the retina. Learn more about the #1 prescribed FDA-approved anti-vascular endothelial growth factor treatment for patients with MEfRVO.

EYLEA is a prescription medicine given by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.

Learn how EYLEA may be able to help

SIGN UP FOR MORE INFORMATION

TIPS FOR LIVING WITH LOW VISION

THE SYMPTOMS OF MEfRVO THROUGH VIRTUAL REALITY

Get the latest materials and communications about EYLEA—and a complimentary pocket magnifier, too.

Just a few changes may make a big difference in your daily routine.

See the common symptoms of MEfRVO with the mobile app, In My Eyes. You can also share the app with your loved ones to help them better understand what you may be experiencing.

IMPORTANT SAFETY INFORMATION
  • EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, moving spots in the field of vision, and increased pressure in the eye.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in patients with DME.

Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.

For U.S. Residents Only

EYLEA AND EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

© 2018, Regeneron Pharmaceuticals, Inc. All rights reserved.
777 Old Saw Mill River Road,
Tarrytown, NY 10591

12/2018
US-LEA-14281d US-LEA-14281d

 

Searching with Lea

Close
MENU